Overview

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Status:
Completed

Trial end date:
2020-11-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab